# Phase 2 Insulin Resistance trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 2 for Insulin Resistance that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Insulin Resistance trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/insulin-resistance

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935278 | Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain Injury | HealthPartners Institute | Phase 2 | Recruiting | Concussion (Diagnosis), Mild Traumatic Brain Injury | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935278) |
| October 20, 2026 | NCT07884058 | IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity | University of Yaounde 1 | Phase 2 | Not yet recruiting | Obesity & Overweight | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884058) |
| August 10, 2026 | NCT07756294 | Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease | Wake Forest University Health Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756294) |
| August 7, 2026 | NCT07753018 | Effects of Curcumin-Piperine Supplementation in Fibromyalgia | Ain Shams University | Phase 2 | Not yet recruiting | Fibromyalgia (FM) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753018) |
| July 29, 2026 | NCT07734870 | Tirzepatide for Treatment of CCCA | Johns Hopkins University | Phase 2 | Recruiting | Central Centrifugal Cicatricial Alopecia (CCCA) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734870) |
| May 8, 2026 | NCT07575438 | Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetes / Type 2 Diabetes, Obesity &... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575438) |
| April 1, 2026 | NCT07505745 | MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | Hudson Biotech | Phase 2 | Recruiting | Prediabetes, Insulin Resistance, Overweight/Obesity | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505745) |
| December 16, 2025 | NCT07286747 | Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) | University Hospital Schleswig-Holstein | Phase 2 | Recruiting | Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286747) |
| November 25, 2025 | NCT07247734 | The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | Sponsor not shown (see the record) | Phase 2 | Recruiting | Type 1 Diabetes, Chronic Inflammation, Insulin Sensitivity | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247734) |
| November 4, 2025 | NCT07224321 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Mannkind Corporation | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224321) |
| September 22, 2025 | NCT07186660 | Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes | University of Virginia | Phase 2 | Recruiting | Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones, Cardiovascular Health | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186660) |
| May 18, 2025 | NCT06978023 | Novel Chinese Medicine Formula for Diabetes | Chinese University of Hong Kong | Phase 2 | Not yet recruiting | Type 2 Diabetes | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06978023) |
| February 11, 2025 | NCT06820281 | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Victor Chang Cardiac Research Institute | Phase 2 | Recruiting | Type 1 Diabetes Mellitus | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820281) |
| March 20, 2024 | NCT06320951 | VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate... | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06320951) |
| February 6, 2023 | NCT05713799 | Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Not yet recruiting | Insulin Resistance, Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05713799) |
| August 12, 2022 | NCT05499702 | The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Type2diabetes | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05499702) |
| July 22, 2022 | NCT05470504 | Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Recruiting | Insulin Receptor Mutation, Partial Lipodystrophy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470504) |
| March 4, 2022 | NCT05266417 | Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease | Gateway Institute for Brain Research | Phase 2 | Recruiting | Parkinson Disease | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05266417) |
| July 30, 2021 | NCT04984226 | Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD | University of California, Davis | Phase 2 | Recruiting | Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04984226) |
| August 13, 2019 | NCT04055428 | NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals | University of Alabama at Birmingham | Phase 2 | Recruiting | Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04055428) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| University of Alabama at Birmingham | 2 |
| Johns Hopkins University | 1 |
| University of Virginia | 1 |
| Hudson Biotech | 1 |
| Chinese University of Hong Kong | 1 |
| HealthPartners Institute | 1 |
| Victor Chang Cardiac Research Institute | 1 |
| [Mannkind Corporation](https://specstream.ai/data/clinical-trials/company/mannkind-corporation) | 1 |
| University of Yaounde 1 | 1 |
| University Hospital Schleswig-Holstein | 1 |
| University of California, Davis | 1 |
| Wake Forest University Health Sciences | 1 |
| Gateway Institute for Brain Research | 1 |
| Ain Shams University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 12 |
| Denmark | 1 |
| China | 1 |
| Hong Kong | 1 |
| Australia | 1 |
| Canada | 1 |
| Germany | 1 |
| Egypt | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Cosmetology schools in the United States](https://specstream.ai/data/businesses/cosmetology-schools/united-states)
- [Dumpling restaurants in the United States](https://specstream.ai/data/businesses/dumpling-restaurants/united-states)
- [Event technology companies in the United States](https://specstream.ai/data/businesses/event-technology-companies/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
